STING1 and neoplasm: In the tumor microenvironment, extracellular vesicle-delivered STING can be taken up by immune cells, potentially triggering a series of events that culminate in antitumor immune responses (Jang et al., 2021; McAndrews et al., 2021; Gao et al., 2022).